Filing excerpt
...entered into a definitive agreement to acquire EyeSouth Partners’ retina business.
sec.gov/Archives/edgar/data/1140859/000110465926033022/tm269555d1_8k.htmRead the full source
Cencora8-K: Software implementation
Acquisition of EyeSouth Partners' business implies upcoming IT system consolidation and integration projects.
What happened
The integration of a new business unit typically requires consolidating disparate IT systems, such as ERP, CRM, and HR platforms. This creates a near-term need for data migration services, system integration platforms, and potentially new enterprise software to create a unified operational environment.
Source
Other signals in this filing (3)
- Capex increaseCencora announces definitive agreement to acquire EyeSouth Partners’ retina business as of March 21, 2026.Capex increase
- Acquisition announcedCencora announces definitive agreement to acquire EyeSouth Partners’ retina businessAcquisition announced
- RestructuringCencora to acquire EyeSouth Partners’ retina business, triggering post-merger integration.Restructuring
Extracted by Autobound
From the Signal API record- Signal
- 8-K: Software implementation
What this signalsFilings often name leadership changes, deals and spending plans.
- Form
- 8-K
- Filed
- Mar 23, 2026
More from Cencora
- 8-KCencora appoints Robert E. Sanchez to Board of Directors, effective October 1, 2026, expanding the board to 11 members.8-K
- GlassdoorConcerns over lack of vision alignment between departments and teamsGlassdoor
- Website changesCencora repositioned its homepage messaging from a transformation-focused AmerisourceBergen story to a broader global pharmaceutical solutions and healthcare provider narrative.Website changes
- Web trafficcencora.com received 499K monthly visits with traffic from 5 countries.Web traffic
- Spin-offFTC Takes a Closer Look at Proposed Cencora-Covetrus MergerSpin-off
- 10-QCencora commits over $1.2B to ERP upgrade and digital transformation projects.10-Q
More 8-K signals at other companies
- SEC 8-K4D Molecular Therapeutics, Inc.4D Molecular Therapeutics initiates Phase 3 trial directly challenging competitor drug aflibercept.SEC 8-K
- SEC 8-KAdeia Inc.Adeia Inc. appoints new CEO Dipti Vachani, effective October 12, 2026, replacing outgoing CEO Paul E. Davis.SEC 8-K
- SEC 8-KAdicet Bio, Inc.Adicet Bio launching pivotal clinical trial in Q4 2026 after positive Phase 1 data for Prula-cel.SEC 8-K
The full record
From the Signal API recordDetails
- CIK
- 1140859
- Accession number
- 0001104659-26-033022
- Timeframe
- Next quarter
- Filing year
- 2026
- Why it matters
- Implementation partner opportunity
- Signal category
- Technology
Extraction
- Confidence
- Medium
- Relevance
- 75%
- Sentiment
- Neutral
- Detected
- Mar 24, 2026
- signal_type
sec-8k- signal_subtype
softwareImplementation
Use this data
Get every 8-K signal for Cencora and the companies you sell to, in the tools you already use.
Ask Claude about it
Connect Autobound to Claude, Claude Code or Cursor with MCP. Then ask: “What changed at Cencora this week?”
Send it to your own tools
The Signal API returns 8-K signals for any list of companies as JSON, for your CRM, warehouse or app.
Try it free
Sign up and spend your free credits on the companies you sell to.
Start Free1,000 free credits
The API returns more than this page shows
This page shows a preview. The full sec-8k record in the Signal API and MCP can also have these 8 fields. Some fields are empty for some signals.
Company
linkedin_urlValue in the APIindustriesValue in the APIemployee_count_lowValue in the APIemployee_count_highValue in the APIrevenueValue in the APIdescriptionValue in the API
Signal
signal_nameValue in the APIassociationValue in the API
Start Free1,000 free creditsUse it in Claude via MCP
Show the full JSONHide the full JSONThe record on this page and the API request
GET /v1/signals/d3925d90-0e90-4639-8935-b0311081e4a7 returns this record as JSON. POST /v1/companies/enrich returns every signal for cencora.com.
{
"signal_id": "d3925d90-0e90-4639-8935-b0311081e4a7",
"signal_type": "sec-8k",
"signal_subtype": "softwareImplementation",
"detected_at": "2026-03-24T07:38:18.687+00:00",
"company": {
"name": "Cencora",
"domain": "cencora.com"
},
"data": {
"detail": "The integration of a new business unit typically requires consolidating disparate IT systems, such as ERP, CRM, and HR platforms. This creates a near-term need for data migration services, system integration platforms, and potentially new enterprise software to create a unified operational environment.",
"metrics": {
"timeframe": "next_quarter"
},
"summary": "Acquisition of EyeSouth Partners' business implies upcoming IT system consolidation and integration projects.",
"excerpts": "...entered into a definitive agreement to acquire EyeSouth Partners’ retina business.",
"relevance": 0.75,
"sentiment": "neutral",
"confidence": "medium",
"source_url": "https://www.sec.gov/Archives/edgar/data/1140859/000110465926033022/tm269555d1_8k.htm",
"filing_date": "2026-03-23",
"filing_year": 2026,
"sales_relevance": "Implementation partner opportunity",
"signal_category": "technology"
}
}
curl https://signals.autobound.ai/v1/signals/d3925d90-0e90-4639-8935-b0311081e4a7 \
-H "X-API-KEY: $AUTOBOUND_API_KEY"curl -X POST https://signals.autobound.ai/v1/companies/enrich \
-H "X-API-KEY: $AUTOBOUND_API_KEY" \
-H "Content-Type: application/json" \
-d '{"domain":"cencora.com","limit":20}'Long text fields are shortened on this page.
Looking up one signal by its id is free. Enrich costs 2 credits per signal returned; a call with no results is free.